Composition for sustained release of human growth hormone

• US 5,654,010 A
• Filed: 06/07/1995
• Issued: 08/05/1997
• Est. Priority Date: 12/02/1992
• Status: Expired due to Fees

• Current Assignee: Alkermes Controlled Therapeutics Inc. II (Alkermes plc)
• Original Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Inventors: Bernstein, Howard, Khan, M. Amin, Johnson, OluFunmi Lily, Ganmukhi, Medha M., Auer, Henry
• Primary Examiner(s): Azpuru, Carlos
• Application Number:
  US08/473,544
• Time in Patent Office: 790 Days
• Field of Search: 424/423, 424/426, 424/489, 424/499, 424/500, 424/501, 424/502, 514/21, 530/399, 530/839
• US Class Current: 424/502
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: Y10S 530/839 Nerves; brain
• CPC Class Codes: Y10T 428/2985 Solid-walled microcapsule from synthetic polymer

Abstract

A composition, and methods of forming and using said composition, for the sustained release of biologically active, stabilized human growth hormone (hGH). The sustained release composition of this invention comprises a polymeric matrix of a biocompatible polymer and particles of biologically active, stabilized hGH, wherein said particles are dispersed within the biocompatible polymer. The method of the invention for producing a composition for the sustained release of biologically active hGH, includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles. The method for using a composition of the invention is a method for providing a therapeutically effective blood level of biologically active, non-aggregated hGH in a subject for a sustained period. In this method, a subject is administered an effective dose of the sustained release composition of the present invention. The method of using the sustained release composition of the present invention comprises providing a therapeutically effective blood level of biologically active, non-aggregated human growth hormone in a subject for a sustained period by administering to the subject a dose of said sustained release composition.

Claims

1. A composition for the sustained release of human growth hormone from a polymeric matrix, comprising:

a) a biocompatible polymer; and

b) particles of metal cation-complexed human growth hormone, wherein said particles are dispersed within the biocompatible polymer.

2. A sustained release composition of claim 1 wherein the biocompatible polymer is selected from the group consisting of poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polycaprolactone, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polycyanoacrylates, poly(p-dioxanone), poly(alkylene oxalate)s, biodegradable polyurethanes, blends and copolymers thereof.

3. A sustained release composition of claim 2 wherein said polymer comprises poly (lactide-co-glycolide).

4. A sustained release composition of claim 1 wherein the metal cation-complexed human growth hormone contains a multivalent metal cation component.

5. A sustained release composition of claim 4 wherein the metal cation component contains Zn⁺².

6. A sustained release composition of claim 1 further comprising a second metal cation component, wherein the second metal cation component is not complexed to said human growth hormone, and wherein the second metal cation component is dispersed within the biocompatible polymer to modulate the release of human growth hormone from the polymeric matrix.

9. A method for providing a therapeutically effective blood level of biologically active, non-aggregated human growth hormone in a subject for a sustained period, comprising administering to the subject a dose of the sustained release composition of claim 1.

7. A composition for the sustained release of human growth hormone from a polymeric matrix, comprising:

a) poly(lactide-co-glycolide);

b) particles of zinc-complexed human growth hormone, with a zinc-to-human growth hormone molar ratio between 4;

1 and 100;

1, wherein said particles are dispersed within the poly(lactide-co-glycolide, and wherein the proportion of human growth hormone in the sustained release composition is between 10 and 30 weight percent; and

c) a second metal cation component, wherein the second metal cation component is not complexed to said human growth hormone, and wherein the second metal cation component is dispersed within the polymeric matrix at a concentration of at least about 1% by weight of polymer.

8. A sustained release composition of claim 7 wherein the particles of zinc-complexed human growth hormone also contain sodium bicarbonate.

10. A sustained release composition of claim 7 wherein said second metal cation component is zinc carbonate.

11. A sustained release composition of claim 10 wherein said zinc carbonate is dispersed within the polymeric matrix at a concentration of at least about 3% by weight of polymer.